Bilodeau K, Arbour C, Mayo S, Ogez D, Savard J. (2022). Predict and act on sleep after blood cancer: the PROSLEEP protocol. Journal of Psychosocial Oncology Research and Practice, 4(S1:563):53

Background/rationale or Objectives/purpose:
Sleep disruptions and unrelenting fatigue are commonly reported after the end of blood cancer treatment. Besides its immediate relevance for patients’ tolerance to daytime activity, poor sleep could also affect their quality of life (QoL). For this reason, blood cancer patients should be provided with personalized tips and support to foster the best possible sleep after treatment. This is particularly important as drugs commonly prescribed to treat sleep complaints in cancer are not recommended for extended use.
Addressing this problem, the PROSLEEP study will provide the first thorough exploration of sleep in recently treated blood cancer patients and its relation to fatigue and QoL.

Methodology or Methods:
We will recruit 68 adults with a primary blood cancer diagnosis (lymphoma, leukemia), who terminated a
treatment in the last 2-4 weeks. Participants’ rest-activity cycle will be monitored for 7 consecutive days/nights at 2-4 weeks and 3 months after the end of blood cancer treatment using actigraphy, sleep diaries, and questionnaires, allowing extraction of quantitative aspects of sleep, as well as more subjective aspects, and interaction with fatigue and QoL. Those with unresolved sleep difficulties at 3 months will be invited to take part in a multimodal intervention focusing on behavioral and selfregulation
skills.

Impact on practice or Results:
Results will be used to further refine the intervention during participating workshops with patient partners and blood cancer association representatives in preparation for a powered RCT.

Discussion or Conclusions:
This study will provide a better understanding of the complexity of sleep disorders in hematological cancer, and potential personalized, patient-centered solutions.

Ce contenu a été mis à jour le 4 octobre 2023 à 14h55.